中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.014 seconds)

    IMPLANTABLE ARTICLE, METHOD OF FORMING SAME AND METHOD FOR REDUCING THROMBOGENICITY
    6.
    发明申请
    IMPLANTABLE ARTICLE, METHOD OF FORMING SAME AND METHOD FOR REDUCING THROMBOGENICITY 审中-公开
    可植入物，其形成方法和降低致血性的方法

    公开(公告)号：WO2007140320A3

    公开(公告)日：2008-11-20

    申请号：PCT/US2007069776

    申请日：2007-05-25

    Applicant: UNIV NANYANG ,  VENKATRAMAN SUBRAMANIAN ,  BOEY YIN CHIANG

    Inventor： VENKATRAMAN SUBRAMANIAN ,  BOEY YIN CHIANG

    IPC: A61F2/00 ,  A61F2/06 ,  A61F13/00

    CPC classification number: A61F2/0077 ,  A61F2/06 ,  A61F2210/0004 ,  A61L27/18 ,  A61L27/34 ,  A61L27/50 ,  A61L27/56 ,  A61L27/58 ,  A61L29/08 ,  A61L31/08 ,  A61L31/10 ,  A61L33/0011 ,  A61L2400/18 ,  A61L2420/06 ,  A61L2420/08 ,  C08L67/04

    Abstract: Endothelialization of a bodily fluid or tissue-contacting, particularly blood- contacting, surface may be accomplished to render that surface substantially non- thrombogenic. Thrombosis may also be mitigated or eliminated by providing an eroding layer on the surface that results in the removal of any thrombus formation as the layer erodes. An implantable device may utilize at least one surface having a plurality of nano-craters thereon that enhance or promote endothelialization. Additionally, an implantable device may have at least one first degradable layer for contacting bodily fluid or tissue and disposed about a central core, and at least one second degradable layer between the first degradable layer and the central core. The first degradable layer has a first degradation rate and the second degradable layer has a second degradation rate which degrades more slowly than the first degradable layer on contact with bodily fluid or tissue.

    Abstract translation: 可以实现体液或组织接触，特别是血液接触表面的内皮化，以使该表面基本上非血栓形成。 也可以通过在表面上提供侵蚀层来减轻或消除血栓形成，从而导致随着层侵蚀而去除任何血栓形成。 可植入装置可以利用其上具有多个纳米凹坑的至少一个表面，其增强或促进内皮化。 另外，可植入装置可以具有用于接触体液或组织的至少一个第一可降解层，并且围绕中心芯设置，以及在第一可降解层和中心芯之间的至少一个第二可降解层。 第一可降解层具有第一降解速率，并且第二可降解层具有在与体液或组织接触时比第一可降解层更缓慢地降解的第二降解速率。

    IMPLANTABLE ARTICLE, METHOD OF FORMING SAME AND METHOD FOR REDUCING THROMBOGENICITY
    7.
    发明申请
    IMPLANTABLE ARTICLE, METHOD OF FORMING SAME AND METHOD FOR REDUCING THROMBOGENICITY 审中-公开
    可植入物，其形成方法和降低致血性的方法

    公开(公告)号：WO2007140320A2

    公开(公告)日：2007-12-06

    申请号：PCT/US2007/069776

    申请日：2007-05-25

    Applicant: NANYANG TECHNOLOGICAL UNIVERSITY ,  VENKATRAMAN, Subramanian ,  BOEY, Yin Chiang

    Inventor： VENKATRAMAN, Subramanian ,  BOEY, Yin Chiang

    IPC: A61F2/06

    CPC classification number: A61F2/0077 ,  A61F2/06 ,  A61F2210/0004 ,  A61L27/18 ,  A61L27/34 ,  A61L27/50 ,  A61L27/56 ,  A61L27/58 ,  A61L29/08 ,  A61L31/08 ,  A61L31/10 ,  A61L33/0011 ,  A61L2400/18 ,  A61L2420/06 ,  A61L2420/08 ,  C08L67/04

    Abstract: Endothelialization of a bodily fluid or tissue-contacting, particularly blood- contacting, surface may be accomplished to render that surface substantially non- thrombogenic. Thrombosis may also be mitigated or eliminated by providing an eroding layer on the surface that results in the removal of any thrombus formation as the layer erodes. An implantable device may utilize at least one surface having a plurality of nano-craters thereon that enhance or promote endothelialization. Additionally, an implantable device may have at least one first degradable layer for contacting bodily fluid or tissue and disposed about a central core, and at least one second degradable layer between the first degradable layer and the central core. The first degradable layer has a first degradation rate and the second degradable layer has a second degradation rate which degrades more slowly than the first degradable layer on contact with bodily fluid or tissue.

    Abstract translation: 可以实现体液或组织接触，特别是血液接触表面的内皮化，以使该表面基本上非血栓形成。 也可以通过在表面上提供侵蚀层来减轻或消除血栓形成，从而导致随着层侵蚀而去除任何血栓形成。 可植入装置可以利用其上具有多个纳米凹坑的至少一个表面，其增强或促进内皮化。 另外，可植入装置可以具有用于接触体液或组织的至少一个第一可降解层，并且围绕中心芯设置，以及在第一可降解层和中心芯之间的至少一个第二可降解层。 第一可降解层具有第一降解速率，并且第二可降解层具有在与体液或组织接触时比第一可降解层更缓慢地降解的第二降解速率。

    A LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY
    8.
    发明申请
    A LIPOSOMAL FORMULATION FOR OCULAR DRUG DELIVERY 审中-公开
    用于药物输送的药物制剂

    公开(公告)号：WO2012021107A3

    公开(公告)日：2012-11-29

    申请号：PCT/SG2011000281

    申请日：2011-08-12

    Applicant: UNIV NANYANG TECH ,  SINGAPORE HEALTH SERV PTE LTD ,  VENKATRAMAN SUBRAMANIAN ,  NATARAJAN JAYAGANESH V ,  WONG TINA ,  BOEY YIN CHIANG FREDDY

    Inventor： VENKATRAMAN SUBRAMANIAN ,  NATARAJAN JAYAGANESH V ,  WONG TINA ,  BOEY YIN CHIANG FREDDY

    IPC: A61K31/5575 ,  A61K9/127

    CPC classification number: A61K9/127 ,  A61K9/0048 ,  A61K31/215 ,  A61K31/5575

    Abstract: The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2 µp?. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.

    Abstract translation: 本发明涉及一种用于眼药物递送的脂质体制剂，其包含（i）包含至少一种脂质双层的脂质体，和（ii）在脂质体中相关的前列腺素药物和/或前列腺素衍生物，其中所述脂质体具有平均直径 小于2μp？ 本发明还涉及包含脂质体制剂和生产用于眼药物递送的脂质体制剂的方法的药物。 另外，本发明涉及治疗或预防眼部疾病的方法，包括将脂质体制剂或药物组合物施用于有需要的受试者。

Patent Agency Ranking